Access to anti-obesity GLP-1s for Medicare-aged adults
Sign up for a free account to read full studies, with full transparency into methods and results, and experience the power of Truveta Studio
Authors: Patricia J. Rodriguez, PhD, MPH ⊕Truveta, Inc, Bellevue, WA, Vincent Zhang, BA ⊕Healthcare Transformation Institute. Department of Medical Ethics and Health Policy, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA , Samuel Gratzl, PhD ⊕Truveta, Inc, Bellevue, WA, Brianna M. Goodwin Cartwright, MS ⊕Truveta, Inc, Bellevue, WA, Duy Do, PhD ⊕Truveta, Inc, Bellevue, WA, Nicholas Stucky, MD, PhD ⊕Truveta, Inc, Bellevue, WA, Ezekiel J. Emanuel, MD, PhD ⊕Healthcare Transformation Institute. Department of Medical Ethics and Health Policy, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Date: April 2, 2023
Abstract
Background
Obesity is common among older adults in the US, but Medicare policies prohibit coverage of anti-obesity medications (AOMs) and may limit access to effective treatment.
Methods
Adults aged 60-69 with overweight or obesity and without Type II diabetes (T2D) were identified from Truveta Data. Data included EHR (encounters, prescriptions, conditions, BMI) and medication dispensing for a collective of US healthcare systems. Eligibility required an outpatient office encounter between June 2021 and January 2024 with a BMI ≥ 27, a negative history of GLP-1 RA use, and a follow-up ≥60 days later. Patients were stratified by Medicare age eligibility (60-64 vs. 65-69) and the proportions prescribed and subsequently dispensed AOM GLP-1 RA were compared.
Results
In total, 413,833 AOM eligible older adults were included in our cohort, with 208,067 (50.3%) Medicare-aged adults and 205,766 (49.7%) adults aged 60-64. Among eligible patients, 0.2% of Medicare-aged patients and 0.4% of patients aged 60-64 were prescribed AOM GLP-1 RA, a significant difference (p < 0.01). Among those prescribed AOM GLP-1 RA, 15.2% of Medicare-aged patients and 22.7% of patients aged 60-64 were dispensed AOM GLP-1 RA within 60 days, a significant difference (p<0.01). In both age groups, prescribing and dispensing were more common for females and those with higher BMI.
Conclusions
Fewer than 1% of older adults with overweight or obesity and without T2D were prescribed an AOM GLP-1 RA. New use of GLP-1 RA was significantly lower for Medicare-aged adults, compared to 60-64-year-olds, with differences occurring at both medication prescribing and dispensing stages. While coverage of AOMs is limited by many insurers, Medicare’s unique prohibition on AOM coverage may contribute to differentially lower use among Medicare-aged adults.